Well, there was not a lot of news out there in biotech land but oddly there is a lot I want to talk about and will work through it over the next couple of days. 1. ARIA Iclusig prescriptions came in weak again with new prescriptions down 26% and only a 9% gain in continuing […]
Week’s Option Activity (7/8~7/12)
The following stocks had notable activity in their options during the past week: $CLDX (7/8): 1,000 AUG 22.0 strike Calls (stock at $21.27) were sold at 1.10 for total proceeds of $110,000. Seller makes money as long as stock trades less than $23.10 by August expiration. This trade is most likely paired with an equivalent […]
July 12- EOD
There have been a couple days of biotech buying, especially it seems in the small cap antibiotic space. Outside of the general performance, there has been some significant news. All in all a couple of interesting days. 1. I was tempted to write a quick update yesterday about the CELG MM-020 results but did not […]
More biotech IPO’s from the first half of 2013
(jointly with Jason Chew and Juan Pedro Rodriguez Serrate) Today, we continue to highlight some recent biotech/life sciences IPOs. Frankly, our earlier post had a much higher quality group of companies seeking to raise money on the public markets. The companies below all have something about their pipeline or lead products that is in some […]
July 10- EOD
Got some interesting news today, which makes this a little more exciting but still not a huge news day (the theme for the week). There will not by a note tomorrow as I need to pick my family up at the airport in the morning and have a doctor appointment in the afternoon. Of course, […]
July 9- EOD
Another slow day, although there was some more interesting news. Biotechs continued to underperform the broader market and I suspect that will be a trend for the next couple of days as the move last week is digested. This is going out a little early because I have to head out before the end of […]
ASTX – Breaking out of the Downtrend Channel
Astex Pharmaceuticals, Inc. (ASTX) -Nasdaq ASTX had an epic run that started at the end of February from the low of $2.94, just after two months of price consolidation, and reached a six year’s high of $6.95 on April 30, 2012. From that point, the stock started a deep technical correction, trading in a downtrend channel […]
Week’s Option Activity (7/1~7/5)
The following stocks had notable activity in their options during the past week: $CLDX (7/1): 7,000 JUL 2.50 strike Calls were bought (stock at $3.25) for 0.90 or $630,000. Buyer makes money if stock is greater than $3.40 by expiration. Also, 4,900 AUG 2.50 Calls were sold for 1.00 or $490,000 total proceeds. Seller makes […]
July 8- EOD
Perhaps we were spoiled last week with the ONXX news but this week seems to be getting off to a slow start. There were some decent sized moves in biotech but in terms of news flow it was a little light. We might be in for a little bit of a breather in terms of […]
INFI – Infinity Pharma, Staying The Course
This has been one heck of a roller-coaster ride. The stock took 8 months to triple in price, and just 2 to give it all back. Shares began to swoon prior to data presentations at ASCO and ICML. We had expected positive results to soothe the market, but this was not the case. Investors focused […]
July 5- Morning Edition
This is another relatively short note as there is not much news today and I suspect most everyone is enjoying an extended Fourth of July weekend. I just wanted to touch on a couple of points and do so early because my office computer is not working well for some reason. It is a royal […]
July 2- EOD–> Midday edition
I wanted to follow up on the discussion of yesterday less with an analysis of the potential dance partners for ONXX but more in terms of where do we go from here. Obviously the speculation in mid and small caps space is who will be next. This list could encompass just about every company but […]
July 1- EOD
Today was the fallout of the AMGN bid for ONXX. There are a couple of aspects of it that I want to touch on and go a little further than my article this morning. 1. In my article I tried to cover the companies that I thought had the most compelling reasons to be interested […]
Week’s Option Activity (6/24~6/28)
The following stocks had notable activity in their options during the past week: $SGEN (6/24): 3,000 SEP 35.0 strike Calls were sold (stock at $30.30) for a credit of 1.20 and 1.25 (1,200 @ 1.25, 1,800 @ 1.20) or $366,000. At the (approximate) same time, 3,000 SEP 25.0/20.0 strike Put spreads were bought for 1.15 […]
June 28- EOD
Not much of a lot of new today but there were some interesting tidbits. 1. BIIB spiked higher today on the back of SNY news. The EMA granted Aubagio exclusivity and traders immediately wanted to tie this into the debate over BG12 exclusivity in the EU. I am not sure that this is anything more […]
June 27- EOD
I thought today would be a much better day in the market for biotechs and they looked strong early but did not seem to have any real follow through. Not that it was a bad day; rather, it seemed to show more strength early. Still some stock specific stories to talk about. 1. CELG signed […]
June 26- EOD
Generally it was a good bounce back day for a lot of biotechs, although there were some pockets of underperformance. That being said, this is a positive day but the real test will be when these stock get to their 50-day moving average and whether they can decisively move back above them. Until then I […]
Biotech IPO’s hot in the first half of 2013
(jointly with Jason Chew and Juan Pedro Rodriguez Serrate) To say biotech IPOs have been hot seems like an understatement. The past year has been an open feeding frenzy for biotech companies looking to raise capital on the public markets. It would seem there is significant pent up pent up supply and demand for these […]
June 25- EOD
It was an odd day in the market as it was strong but many biotechs appeared weak. I am going to focus exclusively today on SGEN as we got more details and I have been digging into the weeds to try and get a handle on what this means. So there were more details on […]
